Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide

Affiliations

• ¹ Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
• ² Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
• ³ GROM-L (Gruppo Romano-Laziale MDS), Rome, Italy.
• ⁴ Italian Group for Adult Hematologic Diseases (GIMEMA) Foundation, Rome, Italy.
• ⁵ Department of Translational and Precision Medicine-Az., Policlinico Umberto I-Sapienza University, Rome, Italy.
• ⁶ Hematology Unit, Sant'Eugenio Hospital, Rome, Italy.
• ⁷ Belcolle Hospital, Viterbo, Italy.
• ⁸ Hematology Dep, Az. Osp., San Giovanni-Addolorata, Rome, Italy.
• ⁹ Hematology, "Sant'Andrea" Hospital-Sapienza, University of Rome, Rome, Italy.
• ¹⁰ Hematology, Pescara Hospital, Pescara, Italy.
• ¹¹ Hematology, ASL Roma 1, Rome, Italy.
• ¹² Hematology and Hematopoietic Stem Cells Transplant Unit, AO San Camillo-Forlanini, Rome, Italy.
• ¹³ Hematology Unit, Department of Research and Clinical Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
• ¹⁴ Hematology and Stem Cell Transplantation Unit, University Campus Bio-Medico, Rome, Italy.
• ¹⁵ Department of Hematology, Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, Roma, Italy.
• ¹⁶ Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. voso@med.uniroma2.it.
• ¹⁷ GROM-L (Gruppo Romano-Laziale MDS), Rome, Italy. voso@med.uniroma2.it.
• ¹⁸ Santa Lucia Foundation, IRCCS, Neuro-Oncohematology, Rome, Italy. voso@med.uniroma2.it.